Weekly Spotlight - 07.11.24

Community

We want to hear your story!

Fill in the form to share your experiences and any challenges you’ve faced living with your condition, for a chance to be featured in one of our weekly newsletters!

PBC Foundation: Project 90:90

“We are excited to announce the launch of Project 90:90, a PBC Community initiative to Provide Better Care with the ambition that 90% of PBC patients receive 90% of care recommended by the care standards in PBC guidelines.”

In the News

Sweden's Hepatology Research: A Legacy of Collaboration and Success

The Swedish Hepatology Research Group (SWEHEP) has fostered collaboration in liver disease research for 40 years, achieving significant advancements in understanding and treating conditions like autoimmune hepatitis and primary sclerosing cholangitis. Their success is attributed to teamwork, trust, and a commitment to improving patient outcomes.

Neuromyelitis Optica with Sjogren's and Biliary Cholangitis: A Case Study

A 30-year-old woman with Neuromyelitis Optica Spectrum Disorder, Sjogren's Syndrome, and Primary Biliary Cholangitis experienced severe symptoms. After treatment with steroids, immunoglobulin, and rituximab, her condition improved significantly. This rare case highlights the importance of recognising overlapping autoimmune disorders for effective treatment.

Elafibranor Shows Promise for Advanced Primary Biliary Cholangitis Treatment

Elafibranor, a promising treatment for primary biliary cholangitis (PBC), showed significant biochemical response in both early and advanced stages. Patients receiving elafibranor experienced better outcomes than those on placebo. This suggests elafibranor is a well-tolerated option for advanced PBC, offering hope for improved patient care.

Ocaliva's Market Withdrawal: Implications for PBC Treatment and Future Options

The EMA recommends withdrawing Ocaliva for PBC due to unproven benefits and potential risks. Patients should consult doctors about stopping it. UDCA remains the go-to treatment, with fibrates as a backup. New drugs are on the horizon, promising better outcomes. Stay tuned for more liver-friendly options!